BioCentury
ARTICLE | Clinical News

Merck discontinues preladenant for PD

May 24, 2013 12:34 AM UTC

Merck & Co. Inc. (NYSE:MRK) said it no longer plans to submit regulatory applications for preladenant to treat Parkinson's disease after an initial review of data from three double-blind Phase III tri...